BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24579326)

  • 1. [Loss of hbs antigen after treatment with analogues: infrequent but stable and beneficial].
    Chanson P; Pariente A
    Rev Prat; 2013 Dec; 63(10):1357. PubMed ID: 24579326
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
    Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
    J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection.
    Lee HW; Park JY; Kim SG; Tak WY; Yim HJ; Jang BK; Kim MY; Kim BI; Lee JW; Yoon KT; Cheong JY; Kwon SY; Kim TY; Bae SH; Seo YS; Kwon JH; Kim DJ; Kim JK; Jeong SW; Myoung S; Ahn SH; Han KH;
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2811-2813.e1. PubMed ID: 30731195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers.
    Kim HS; Baatarkhuu O; Lee HW; Park JY; Kim DY; Ahn SH; Song K; Han KH; Kim BK; Kim SU
    Liver Int; 2019 Jan; 39(1):81-89. PubMed ID: 30280461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
    J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Kim JH; Sinn DH; Kim K; Kim H; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Nov; 10(6):939-947. PubMed ID: 27282264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
    Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ
    Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
    Piroth L; Pol S; Miailhes P; Lacombe K; Lopes A; Fillion A; Loustaud-Ratti V; Borsa-Lebas F; Salmon D; Rosenthal E; Carrat F; Cacoub P;
    Liver Int; 2015 Aug; 35(8):1950-8. PubMed ID: 25559645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
    Boettler T; Thimme R
    Dig Dis; 2015; 33(4):608-12. PubMed ID: 26159281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus-related Cirrhosis Patients Receiving Antivirals.
    Yim SY; Lee JH; Ahn H; Kim SU; Kim SG; Kim YS; Kim JH; Choe WH; Kim TY; Jung YK; Suh SJ; Suk KT; An H; Yim HJ; Seo YS; Um SH
    J Clin Gastroenterol; 2016 Sep; 50(8):676-85. PubMed ID: 27203430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis.
    Chon YE; Park JY; Myoung SM; Jung KS; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH
    Am J Gastroenterol; 2017 Jun; 112(6):882-891. PubMed ID: 28374814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study.
    Ahn J; Lim JK; Lee HM; Lok AS; Nguyen M; Pan CQ; Mannalithara A; Te H; Reddy KR; Trinh H; Chu D; Tran T; Lau D; Leduc TS; Min A; Trong Le L; Bae H; Van Tran S; Do S; Hann HW; Wong C; Han S; Pillai A; Park JS; Tong M; Scaglione S; Woog J; Kim WR
    Am J Gastroenterol; 2016 Sep; 111(9):1297-304. PubMed ID: 27325221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
    Hosaka T; Suzuki F; Kobayashi M; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Liver Int; 2010 Nov; 30(10):1461-70. PubMed ID: 20840396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma.
    Chan AC; Chok KS; Yuen WK; Chan SC; Poon RT; Lo CM; Fan ST
    Arch Surg; 2011 Jun; 146(6):675-81. PubMed ID: 21690443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
    Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation.
    Nishikawa H; Nishijima N; Enomoto H; Sakamoto A; Nasu A; Komekado H; Nishimura T; Kita R; Kimura T; Iijima H; Nishiguchi S; Osaki Y
    Medicine (Baltimore); 2016 Sep; 95(36):e4832. PubMed ID: 27603400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.